Comparison of IV Nalbuphine Versus Ibuprofen for Postoperative Pain Control in Cesarean Section

The local data is insufficient to directly compare IV nalbuphine versus ibuprofen among people in this region. The findings of this study would add to the existing data and would be helpful for health providers to opt for a better option for postoperative pain relief following a cesarean section under general anesthesia.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pain Management Agnosia Nervous System Diseases Neurobehavioral Manifestations Neurologic Manifestations Pathological Conditions, Signs and Symptoms Perceptual Disorders Signs and Symptoms

Age range

18 year–45 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Nishtar Hospital, Multan, Punjab Province, Pakistan

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Parturient females
Aged between 18-45 years
Gestational age above 32 weeks
ASA class I to II
Anticipated hospital stay for at least 24 hours

Exclusion criteria

Known allergy to the drugs being evaluated in this study
Renal and/or hepatic impairment (as per medical record)
History of bronchial asthma or history or risk of intracranial hemorrhage (as per medical record)
Low platelets count (<70000) or with bleeding diathesis
BMI above 30 kg/m2

Treatment and study plan

Ibuprofen

Drug

Patients were given 800 mg Ibuprofen in 200 cc normal saline intravenously at the time of arrival in the ward.

Nalbuphine

Drug

Patients received 20 mg nalbuphine in 200 cc normal saline IV at the time of arrival in the ward.

Primary outcomes

Efficacy in pain control

Time frame: At 1 hour, 3 hours, and 6 hours.

Outcome was noted in the form of VAS pain scores. Scores from 1 to 3 were labeled as mild pain, 4 to 6 as moderate pain, and 7 to 10 as severe pain.

Sponsors and collaborators

Lead sponsor

Muhammad Aamir Latif

Other

Registry information

Important dates

Study start: 2024
Primary completion: 2024
Study completion: 2024
First posted: Sep 19, 2024
Registry last updated: Sep 19, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed